Breast-cancer adjuvant therapy with zoledronic acid. - Wikidata - awgldk - TriplyDB

Breast-cancer adjuvant therapy with zoledronic acid.

Breast-cancer adjuvant therapy with zoledronic acid.

http://www.wikidata.org/entity/Q42620139

about

Bisphosphonates in the adjuvant setting of breast cancer therapy--effect on survival: a systematic review and meta-analysis Pharmacologic management of bone-related complications and bone metastases in postmenopausal women with hormone receptor-positive breast cancer Bisphosphonates as anticancer agents in early breast cancer: preclinical and clinical evidence Collapsing focal segmental glomerulosclerosis following long-term treatment with oral ibandronate: case report and review of literature Human isoprenoid synthase enzymes as therapeutic targets Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients Where Do Bone-Targeted Agents RANK in Breast Cancer Treatment?Bisphosphonates in breast cancer Zoledronic acid as an adjuvant therapy in patients with breast cancer: a systematic review and meta-analysis Current treatment of early breast cancer: adjuvant and neoadjuvant therapy Bone antiresorptive agents in the treatment of bone metastases associated with solid tumours or multiple myeloma Randomized Controlled Trial of Zoledronic Acid plus Chemotherapy versus Chemotherapy Alone as Neoadjuvant Treatment of HER2-Negative Primary Breast Cancer (JONIE Study)Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 Bisphosphonate-related osteonecrosis of the jaw: data from the French national pharmacovigilance database.FemZone trial: a randomized phase II trial comparing neoadjuvant letrozole and zoledronic acid with letrozole in primary breast cancer patients.Stabilization of bone marrow infiltration by metastatic breast cancer with continuous doxorubicin Influence of zoledronic acid on disseminated tumor cells in bone marrow and survival: results of a prospective clinical trial.Zoledronic acid has differential antitumor activity in the pre- and postmenopausal bone microenvironment in vivo Zoledronic acid effectiveness against breast cancer metastases - a role for estrogen in the microenvironment?Aromatase inhibitors-induced bone loss in early breast cancer.The microenvironment matters: estrogen deficiency fuels cancer bone metastases Pharmacologic inhibition of bone resorption prevents cancer-induced osteolysis but enhances soft tissue metastasis in a mouse model of osteolytic breast cancer.The best of both worlds - managing the cancer, saving the bone.Targeted and Osteo-Oncologic Treatment in Early Breast Cancer: What Is State-of-the-Art and What Might Become so within the Next 5 Years?Pathophysiology of Bone Remodelling and Current Therapeutic Approaches.Breast Cancer 2012 - New Aspects Effects of zoledronic acid and the association between its efficacy and γδT cells in postmenopausal women with breast cancer treated with preoperative hormonal therapy: a study protocol.Adjuvant therapy with zoledronic acid in patients with breast cancer: a systematic review and meta-analysis.Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Repurposing of bisphosphonates for the prevention and therapy of nonsmall cell lung and breast cancer Bisphosphonates inactivate human EGFRs to exert antitumor actions.Survival benefit of zoledronic Acid in postmenopausal breast cancer patients receiving aromatase inhibitors Real-time intravital imaging establishes tumor-associated macrophages as the extraskeletal target of bisphosphonate action in cancer Addressing the controversy: do bisphosphonates directly affect primary tumors?Adjuvant bisphosphonates in breast cancer treatment Effect of bisphosphonate use on risk of postmenopausal breast cancer: results from the randomized clinical trials of alendronate and zoledronic acid.Bone remodeling markers and bone metastases: From cancer research to clinical implications Latest advances in the medical treatment of cancer: a 2011 snapshot.Treatment and Prevention of Bone Metastases from Breast Cancer: A Comprehensive Review of Evidence for Clinical Practice

P2860

Q21132670-94A373C0-734D-4D0B-867A-36D3DFDC2B07 Q26746212-852C8A5C-10B1-4FB8-A1BA-1C14FABF3EFA Q26795493-50B1217A-EA3B-4508-BC2C-7DC230618EB7 Q26801348-4D2C2F5E-207C-4F9A-A728-6B78930E8AEB Q26822639-28E13A1C-540B-4F43-B973-93B846F27D03 Q26824762-C1DBCADB-11D6-4936-A9AD-4B79FB30F428 Q26849473-DEFF549B-D41E-45FF-8F67-E225722B084B Q26859326-EEA32270-6002-4C81-AC47-9FAE7018E37D Q26861745-0B82F85C-1FBC-44A0-A56F-E8C7740DB2D2 Q27011658-66EFC1F0-7BA7-40D1-B9B5-1DE6CE7A92A7 Q28081996-45170D76-80B3-4AEC-9CF9-892FCCE7FEC6 Q28551320-543D45A5-BEDB-490C-A2B4-B722E70DE1A4 Q30275126-971DFE58-7E31-47ED-BA1F-80E424A6C839 Q30543788-CB35263B-A449-4818-AD83-2A952004A6AD Q31108809-33758526-1948-42B4-8365-C30705BCA546 Q31150676-68C85594-7583-4B02-8422-34755DAA9B89 Q33422353-B0DCF3F2-E19C-45CA-8F74-F945B20DC904 Q33587199-65680CA1-685A-408D-B967-B7DFB634C392 Q33692900-D87652AD-5D95-449F-B51C-D11D4223D9F4 Q33739204-424F0A39-A6CF-4DEF-B791-ECA041653FE1 Q33752867-740C5551-7995-4374-83D9-8BE686A5F87D Q33772299-79B2B68F-5854-4E70-920C-E43E4137DD1E Q33882079-16DEAFB6-7063-41A8-8B04-312C978CA721 Q33920055-70CB3A3F-453D-49B8-AF25-F5BC97774B2A Q34042715-CD29B0F7-537D-4B6D-B5ED-6348ADADF21F Q34209614-FCC0DFD2-CABE-4C11-8AFF-79200B86CA02 Q34209663-8D7701D2-7C72-4575-BDB9-F4830F8BC13A Q34581699-74EC0C90-1AE0-49D5-8EFD-13A380AB0D65 Q34583705-8DD4BF7D-3CDD-4D3C-8244-FEAD7AA0166F Q34655579-8144F236-C8A1-457A-A2C6-3F8D53B7BC8A Q34752800-06471A7B-5095-4E8A-9375-FB99DC05C50A Q34752876-B439D0D9-43D9-4235-8B08-2B1F36E1F340 Q34779663-EDF10D74-F7BB-404C-9043-9D9A3BFAD9D4 Q34945422-EC0773E3-2F76-440C-B0DC-41A7097182FA Q34970986-9628E742-8587-4981-A0B9-B8371C8D06ED Q35066934-056488B0-9F68-4962-86D1-9AD867AAE870 Q35431110-F77382B7-965F-4F74-AB2E-49477FB312AB Q35531006-C73699EE-D6DC-456D-8BF2-D6FEA77710D7 Q35628127-CEC40747-FD0B-41A6-92CE-751D0C259120 Q35667196-0AF83A1D-A6CB-4EF4-A504-2A4D38D56DB1

P2860

Breast-cancer adjuvant therapy with zoledronic acid.

http://www.wikidata.org/entity/Q42620139

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Breast-cancer adjuvant therapy with zoledronic acid.

@en

Breast-cancer adjuvant therapy with zoledronic acid.

@en-gb

Breast-cancer adjuvant therapy with zoledronic acid.

@nl

type

label

Breast-cancer adjuvant therapy with zoledronic acid.

@en

Breast-cancer adjuvant therapy with zoledronic acid.

@en-gb

Breast-cancer adjuvant therapy with zoledronic acid.

@nl

prefLabel

Breast-cancer adjuvant therapy with zoledronic acid.

@en

Breast-cancer adjuvant therapy with zoledronic acid.

@en-gb

Breast-cancer adjuvant therapy with zoledronic acid.

@nl

P1433

Q42620139-2FAF127F-D3E1-4281-AED9-8D2B8107D590

P1476

Q42620139-34AFFFA9-8243-4A09-98ED-8BF78583523F

P2093

Q42620139-098608D4-DC43-42C5-B28F-98A8EAE8FA82

Q42620139-149CE858-8453-469D-B305-9032CB7145AD

Q42620139-16DF0002-5EA1-4D0A-8448-DCD5289097A9

Q42620139-192EAD49-7A91-45C0-9BB0-4BCB40CF01CA

Q42620139-277B4068-3638-4C21-94B5-603E9C2978D0

Q42620139-382E7A15-D465-41AD-889F-7ECD297F345C

Q42620139-54DA07D8-FB79-4A7D-A8EA-7159E407FBCA

Q42620139-58904B08-AC7D-4EAC-90B8-E5C664667DC8

Q42620139-76A1A4C4-1069-4CA3-9A9E-6B199E4467AC

Q42620139-7DD8F5F7-11DC-4924-963C-ECC28875896F

P304

Q42620139-2B0E12ED-0C43-4610-83D6-27687C8A14EB

P31

Q42620139-0C5BAA3D-322C-4563-95E4-E052426E2796

P356

Q42620139-51C4BCDE-3713-40AA-8CD5-DA2B121AC5C6

P407

Q42620139-712A2779-BB31-4BA9-AEB0-0A8799331050

P433

Q42620139-7F4ACD86-06D5-4223-B48E-43AE6AD6DF09

P478

Q42620139-485F87C7-0F5B-4AC2-A1C8-951BB10CE6DA

P50

Q42620139-2AA2D000-69C7-4BAC-BC44-4DA987071D9C

Q42620139-CED76FCB-FFF1-4EB1-B52E-CF643E310678

P5530

Q42620139-1BBBC385-90C0-43AB-AC9C-07E6EB9E4F0F

P577

Q42620139-214D2EDF-9DAE-4A54-A6C0-60EB89516333

P5875

Q42620139-09BA348B-B5DD-472D-8266-D1714FC19B49

P6179

Q42620139-99B55835-015E-4D6A-8F6D-C518D715FDB9

P698

Q42620139-B3BE51F4-B66A-421B-92EF-260705A51ADD

P953

Q42620139-3B62F8CB-B559-49B4-ABD0-3F84AFA0A0F6

P356

P1433

The New England Journal of Medicine

P1476

Breast-cancer adjuvant therapy with zoledronic acid.

@en

P2093

AZURE Investigators

http://www.w3.org/2001/XMLSchema#string

Claire Davies

http://www.w3.org/2001/XMLSchema#string

Claire Gaunt

http://www.w3.org/2001/XMLSchema#string

David Cameron

http://www.w3.org/2001/XMLSchema#string

David Dodwell

http://www.w3.org/2001/XMLSchema#string

Diana Ritchie

http://www.w3.org/2001/XMLSchema#string

Jennifer Peterson

http://www.w3.org/2001/XMLSchema#string

Julia Pugh

http://www.w3.org/2001/XMLSchema#string

Maccon Keane

http://www.w3.org/2001/XMLSchema#string

Miguel Gil

http://www.w3.org/2001/XMLSchema#string

P304

1396-1405

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1105195

http://www.w3.org/2001/XMLSchema#string

P407

P433

15

http://www.w3.org/2001/XMLSchema#string

P478

365

http://www.w3.org/2001/XMLSchema#string

P50

Peter Barrett-Lee

P5530

381006

http://www.w3.org/2001/XMLSchema#string

P577

2011-09-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51717191

http://www.w3.org/2001/XMLSchema#string

P6179

1016139121

http://www.w3.org/2001/XMLSchema#string

P698

21995387

http://www.w3.org/2001/XMLSchema#string

P953